http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#Head http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#assertion http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#provenance http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#pubinfo http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#assertion http://purl.obolibrary.org/obo/DOID_2349 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_2349 http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01255 http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#association http://www.w3.org/2000/01/rdf-schema#label "Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncratic reaction to sympathomimetic amines, glaucoma Agitated states Patients with a history of drug abuse During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result) [ See Drug Interactions (7.3) Advanced arteriosclerosis ( 4 Symptomatic cardiovascular disease ( 4 Moderate to severe hypertension ( 4 Hyperthyroidism ( 4 Known hypersensitivity or idiosyncrasy to sympathomimetic amines ( 4 Glaucoma ( 4 Agitated states ( 4 History of drug abuse ( 4 During or within 14 days following the administration of monoamine oxidase inhibitors (MAOI) ( 4 7.3" http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB01255 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#provenance http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#pubinfo http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#sig http://purl.org/nanopub/x/hasSignature aho1PoHFhoJFojcpMyQKZGb7HKyl149YlzPcaYrfwnZ81Sun1SF3GpfuHs5Jbdz5PsbPnsoShdoD7MDUAz3IHjncWvIhWhezpBs5DKHKs4M7Xbsckl0AjhHeTFOtdDLCA4eXJ3b96Ey6ZG7X4xbTyLkxhy6pSILf7RrHvn7S7iM= http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU http://purl.org/dc/terms/created 2021-08-23T13:00:18.351+02:00 http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY